Detalles de la búsqueda
1.
Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.
Br J Haematol
; 204(1): 160-170, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37881141
2.
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial.
Ann Surg Oncol
; 31(6): 4073-4083, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38459418
3.
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry.
Int J Cancer
; 148(6): 1478-1488, 2021 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33038277
4.
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Lancet
; 393(10184): 1948-1957, 2019 05 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30982686
5.
ASO Visual Abstract: Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer-The Randomized Multicenter Phase II NEPAFOX Trial.
Ann Surg Oncol
; 31(6): 4121-4122, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38575722
6.
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Lancet Oncol
; 17(12): 1697-1708, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27776843
7.
Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.
Trials
; 24(1): 591, 2023 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37715270
8.
CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach.
J Cancer Res Clin Oncol
; 144(3): 559-569, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29285668
Resultados
1 -
8
de 8
1
Próxima >
>>